The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Belamaf plus DRd in TI patients with newly diagnosed myeloma: the Phase I/II BelaDRd study
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, provides insight into the BelaDRd trial (EUCT-2024-515634-32), a Phase I/II open-label study that evaluated a quadruplet combination of belantamab mafodotin, daratumumab, lenalidomide, and dexamethasone in transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (MM). Dr Dimopoulos highlights the promising activity of the combination regimen and notes that it was well tolerated, with few discontinuation events, despite the older age and frailty of many patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
